Sunrise New Energy Announces Invention of Porous Carbon-Coated Graphite Composite Material for Energy Storage Batteries, Targeting High-Performance Storage for Data Centers

Rhea-AI Summary

Anixa Biosciences (NASDAQ: ANIX) announced that final results from its Phase 1 alpha-lactalbumin (aLA) breast cancer vaccine trial will be presented at the 2025 San Antonio Breast Cancer Symposium on December 11, 2025 (5:00–6:30 PM CST, Poster PS4-06-19, Abstract 765).

The trial was conducted at Cleveland Clinic and funded by a U.S. Department of Defense grant. Comprehensive blood and tissue analyses are underway and a full report will be submitted to the Department of Defense and the U.S. Food and Drug Administration to inform Phase 2 planning.

Positive

• Final Phase 1 results scheduled for presentation on Dec 11, 2025
• Trial conducted at Cleveland Clinic with institutional involvement
• Funded by a U.S. Department of Defense grant
• Data will be submitted to FDA to inform Phase 2 planning

Negative

• Press release does not disclose quantitative efficacy or safety metrics

Key Figures

Private placement gross proceeds $5,600,000 7,000,000 shares and 3,500,000 warrants at $0.80 (Regulation S, 6-K 2025-11-19)

Public offering gross proceeds $1,650,000 Class A shares at $0.55 (424B5 dated 2025-10-03)

Public offering net proceeds $1,624,000 After ~$26,000 expenses (424B5 dated 2025-10-03)

Earlier public offering gross $550,000 Class A shares at $0.55 (424B5 dated 2025-09-23)

Net loss (example period) $23,124,402 Consolidated net loss referenced in 424B5 dated 2025-10-03

Intercompany loans $6,188,307 Historical intercompany loans disclosed in 424B5 dated 2025-10-03

Joint venture capital US$1.0 million Initial capital for Alchemistica Inc. JV (6-K dated 2025-08-08)

Abstract Number 765 Breast cancer vaccine Phase 1 final results abstract at SABCS 2025

Market Reality Check

$1.03 Last Close

Volume Volume 378,057 vs 20-day average 233,317 (relative volume 1.62) indicates elevated trading interest ahead of/around this news. high

Technical Price $1.03 is trading above the 200-day MA of $0.99 while still 44.62% below the 52-week high.

Peers on Argus 1 Up

Sector peers showed mixed moves: CCTG down 7.41%, DFLI roughly flat, FLUX and GWH up modestly, and OESX up 9.19%. Only one peer (APWC) appeared in momentum scans, moving up 4.04% without news. This pattern points to stock-specific factors for EPOW rather than a broad sector rotation.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 05	Battery patent grant	Positive	-7.0%	China patent on fast-charging silicon-carbon composite anode materials.
Dec 04	Solid-state patent	Positive	+6.0%	Patent for lithium cerate–coated graphite iron oxide anode method.
Dec 04	Pilot project funding	Positive	+6.0%	USD 345,000 award for solid-state battery and key materials pilot.
Dec 02	Supply contract	Positive	-0.9%	One-year USD 30M contract for 10,000 tons of graphite anode.
Oct 22	AI control patent	Positive	+1.9%	Patent for AI-driven multivariable particle size control system.

Pattern Detected

Recent technology and contract news has often been positive while price reactions were mixed, with both aligned gains and occasional selloffs on good news.

Recent Company History

Over the last few months, Sunrise New Energy reported several technology and commercial milestones. On Dec 2, it signed a 10,000-ton, roughly $30 million annual supply contract for synthetic graphite anode materials. On Dec 4–5, the company secured a USD 345,000 pilot project grant and multiple patents for solid-state and fast-charging anode technologies. Earlier, on Oct 22, it highlighted an AI-driven particle size control patent. Price reactions alternated between gains and pullbacks, indicating investors have not consistently rewarded positive developments.

Market Pulse Summary

This announcement adds to Sunrise New Energy’s string of developments in advanced battery and energy‑storage materials, complementing prior patents, pilot funding of USD 345,000, and a 10,000‑ton anode supply contract valued near $30 million. At the same time, recent public and private offerings at $0.55–$0.80, historical net losses of $23,124,402, and going‑concern language in filings underline financial and dilution risk. Investors may watch for revenue realization, cash usage, and further capital‑raising activity.

Key Terms

phase 1 medical

"final results from the Phase 1 clinical trial of its breast cancer vaccine"

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

phase 2 medical

"to inform FDA discussions and advance Phase 2 development plans"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

immunogenicity medical

"evaluated the safety and immunogenicity of an alpha-lactalbumin (aLA) vaccine"

Immunogenicity is the ability of a substance, such as a vaccine or medication, to provoke an immune response in the body. It matters to investors because high immunogenicity can affect the effectiveness and safety of a product, potentially leading to increased costs or regulatory challenges. Understanding immunogenicity helps assess the long-term viability and market potential of pharmaceutical and biotech investments.

alpha-lactalbumin medical

"immunogenicity of an alpha-lactalbumin (aLA) vaccine for breast cancer"

Alpha-lactalbumin is a protein naturally found in mammalian milk that helps produce lactose (milk sugar) and supplies key amino acids, notably tryptophan. Investors care because it is used as an ingredient in infant formulas, medical nutrition and dietary supplements, and can affect product claims, manufacturing costs and regulatory review—think of it as a specialty ingredient that can change a food or drug product’s nutritional value and market appeal.

poster presentation technical

"Poster Presentation: Thursday, December 11, 2025, 5:00–6:30 PM CST"

A poster presentation is a visual display of information, often used to share research findings or ideas at conferences or meetings. It usually consists of a large printed poster that summarizes key points, allowing viewers to quickly understand the main message and ask questions. For investors, it highlights important developments or insights in a clear, accessible way, helping them stay informed about new opportunities or trends.

form 6-k regulatory

"has filed a Form 6-K to furnish materials related to its upcoming"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

regulation s regulatory

"issued the shares and warrants under Regulation S, which applies to offerings"

Regulation S is a set of rules that allows companies to sell securities (like shares or bonds) to investors outside the United States without having to follow all U.S. securities laws. It matters because it makes it easier for companies to raise money from international investors while still complying with U.S. regulations.

AI-generated analysis. Not financial advice.

Phase 1 Data Highlights Potential of First-in-Class Vaccine to Transform Breast Cancer Treatment and Prevention

Comprehensive Results, Supported by U.S. Department of Defense Funding, to Inform FDA Discussions and Advance Phase 2 Development Plans

SAN JOSE, Calif., Sept. 22, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that final results from the Phase 1 clinical trial of its breast cancer vaccine will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) on Thursday, December 11, 2025.

The trial, conducted at Cleveland Clinic and funded by a grant from the U.S. Department of Defense, evaluated the safety and immunogenicity of an alpha-lactalbumin (aLA) vaccine for breast cancer. The presentation, titled "Final Results of a Phase I Trial of alpha-lactalbumin (aLA) Vaccine for Breast Cancer," will be delivered by Justin Johnson, Ph.D., Program Manager at Cleveland Clinic and co-inventor of the vaccine technology.

With the trial now complete and comprehensive analyses of blood and tissue samples underway, this presentation at SABCS will represent the most detailed data release to date. A full report of the findings will also be submitted to the U.S. Department of Defense, which funded the study, and separately to the U.S. Food and Drug Administration (FDA) to inform upcoming Phase 2 planning discussions.

Presentation Details:

• Abstract Number: 765
• Presentation Number: PS4-06-19
• Presentation Title: Final Results of a Phase I Trial of an Alpha-lactalbumin (aLA) Vaccine for Breast Cancer
• Poster Presentation: Thursday, December 11, 2025, 5:00–6:30 PM CST

"We are very encouraged by the data generated in this human clinical trial, which continues to exceed our expectations," stated Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "This vaccine builds on decades of pioneering preclinical work led by the late Vincent Tuohy, Ph.D. and his team at Cleveland Clinic. His visionary research, has brought us to this pivotal moment—one that has the potential to transform the future of breast cancer prevention and treatment."

About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.

Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808

View original content to download multimedia:https://www.prnewswire.com/news-releases/cleveland-clinic-to-present-final-results-of-phase-1-clinical-trial-for-anixa-biosciences-breast-cancer-vaccine-at-2025-san-antonio-breast-cancer-symposium-302562079.html

SOURCE Anixa Biosciences, Inc.

FAQ

When will Anixa (NASDAQ: ANIX) present Phase 1 aLA vaccine results at SABCS?

Anixa will present on December 11, 2025, 5:00–6:30 PM CST (Poster PS4-06-19, Abstract 765).

What trial site and funding supported Anixa's Phase 1 aLA breast cancer vaccine study?

The trial was conducted at Cleveland Clinic and funded by a U.S. Department of Defense grant.

Will Anixa submit its Phase 1 data to regulators for Phase 2 planning (ANIX)?

Yes. A full report will be submitted to the U.S. Department of Defense and the FDA to inform Phase 2 discussions.

Does the December 11, 2025 SABCS presentation include detailed blood and tissue analyses for ANIX?

The company says comprehensive blood and tissue analyses are underway and will be part of the detailed data release.

Are numeric efficacy or safety results included in the Anixa press release for ANIX?

No. The press release does not provide quantitative efficacy or safety metrics.

Who will deliver the Anixa Phase 1 aLA vaccine presentation at SABCS?

The presentation will be delivered by Justin Johnson, Ph.D., Program Manager at Cleveland Clinic and co-inventor of the vaccine technology.